In which patient population are azole antifungals most likely to cause torsades de pointes?

Azole antifungals, such as fluconazole, itraconazole, and voriconazole, can affect the QT interval on an electrocardiogram, leading to a risk of torsades de pointes, a specific type of polymorphic ventricular tachycardia associated with a prolonged QT interval.

In considering the demographics of patients, females generally have a higher baseline risk of QT interval prolongation due to both hormonal and genetic factors. Additionally, the pharmacokinetics and pharmacodynamics of azole antifungals may interact with other medications or conditions that exacerbate the likelihood of inducing torsades de pointes, thus making this population particularly vulnerable.

The other options do not specifically correlate with an increased risk of torsades de pointes related to azole antifungals. While certain conditions or demographic factors can influence heart rhythm, the known interactions and physiological predispositions in females play a significant role in the likelihood of experiencing torsades de pointes in the context of azole therapy.